Hologic (NASDAQ:HOLX) Upgraded at Evercore ISI

Key Points

• Hologic has been upgraded from an "in-line" to an "outperform" rating by Evercore ISI, with a new target price of $78.00, indicating a potential upside of 15.16% from its current price.
• The company reported a Q3 earnings per share (EPS) of $1.08, beating estimates, and set guidance for Q4 2025 EPS between 1.090-1.120.
• CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock for over $9 million, reducing his ownership stake by 10.08%.

Hologic (NASDAQ:HOLX - Get Free Report) was upgraded by stock analysts at Evercore ISI from an "in-line" rating to an "outperform" rating in a report released on Tuesday, MarketBeat.com reports. The firm presently has a $78.00 target price on the medical equipment provider's stock, up from their prior target price of $69.00. Evercore ISI's price objective would suggest a potential upside of 15.16% from the stock's current price.

Several other brokerages have also recently weighed in on HOLX. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Hologic in a research note on Saturday, September 27th. UBS Group raised their price objective on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and raised their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Argus raised their price target on Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Finally, Morgan Stanley boosted their price target on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $80.15.

Hologic Trading Up 0.6%

NASDAQ HOLX opened at $67.73 on Tuesday. The stock has a market capitalization of $15.06 billion, a price-to-earnings ratio of 28.10, a PEG ratio of 2.31 and a beta of 0.63. Hologic has a one year low of $51.90 and a one year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business's fifty day moving average is $67.03 and its 200-day moving average is $63.18.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm's quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts predict that Hologic will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the business's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.88% of the company's stock.

Hedge Funds Weigh In On Hologic

A number of large investors have recently modified their holdings of HOLX. Chung Wu Investment Group LLC acquired a new stake in Hologic during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd increased its position in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 273 shares in the last quarter. Loomis Sayles & Co. L P purchased a new position in Hologic in the second quarter valued at about $33,000. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic during the first quarter worth about $34,000. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 436 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.